Acknowledgements

The content of this section has been developed in collaboration between COR2ED GmbH (an Independent Medical Education Company) and the experts serving as Scientific Directors on this programme:

  • Dr. Guillem Argilés, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
  • Prof. Dr. Siegfried Segaert, University Hospital Sint-Rafaël, Leuven, Belgium
  • Christine Boers-Doets, MSc, Leiden University Medical Center, Leiden, The Netherlands
  • Dr. Josep Tabernero, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Medical writing support was provided by Mark English, PhD, of COR2Ed GmbH. Subsequently the content was donated to the European Society for Medical Oncology (ESMO).

Bayer Healthcare

ESMO, COR2ED GmbH and the Scientific Directors wish to thank Bayer HealthCare for their support with an Independent Medical Grant. Within the context of this Independent Medical Grant Bayer HealthCare had no influence over the content.

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.

At the time of the creation of this content, there were no clinical study outcome-based guidelines for the management of these skin toxicities of Multikinase Inhibitors. As such, treatment algorithms here were largely compiled from expert statements, literature review (of review articles, reports of small cohort studies and limited data from small prospective, randomised clinical trials) and expert guidance from the Scientific Directors as listed above.

Last update: 22 August 2014